Risk Agreements for Experimental Medicines

Summary#

This bill would label several groups of medicines as “experimental” and set strict conditions on their use in British Columbia. It would block doctors, pharmacists, and other practitioners from prescribing, dispensing, or giving those drugs unless the drug’s wholesaler (the distributor) signs a risk management agreement with the province. The stated goal is to manage risk, pay patients who are harmed, and protect the health system from unexpected costs.

Key changes:

• Names these as “experimental drugs classes”: COVID‑19 vaccines used in the provincial program; drugs used in harm‑reduction/safer‑supply programs; puberty blockers and other hormones for gender transition; and selective serotonin reuptake inhibitors (SSRIs) used for mental health.
• Lets the health minister add more drug classes based on use, uncertainty about long‑term safety or effectiveness, potential health‑system costs, or other public‑health factors.
• Bans practitioners from using a drug in an experimental class unless the wholesaler signs a risk management agreement acceptable to the minister and any minister‑set conditions are followed.
• According to the bill’s explanatory note, those agreements must include a patient compensation fund and an indemnity (the wholesaler pays back certain health‑system costs to government).
• Allows the minister to require such agreements as a condition for public funding or participation in public health initiatives.
• Allows the minister to set conditions including monitoring and reporting by wholesalers on how the drug is prescribed, dispensed, and administered.
• States this Act overrides other provincial laws if there is a conflict.
• Start date will be set later by regulation (not immediate).

What it means for you#

• Patients receiving listed drugs

  • COVID‑19 vaccines, safer‑supply/harm‑reduction medications, gender‑affirming hormones or puberty blockers, and SSRIs would only be available if the wholesaler signs a risk management agreement and ministerial conditions are met.
  • If a wholesaler does not sign, access to that drug in B.C. could stop or be delayed.
  • A compensation fund would be set up by wholesalers to pay affected patients who are harmed, but how it would work is not detailed in the bill text.
  • Wholesalers may have to report data about the use of these drugs to the minister. The bill does not spell out what data would be shared or how privacy would be protected.

• Health care practitioners (prescribers, pharmacists, nurses who administer)

  • Must not prescribe, dispense, or administer a listed drug unless the wholesaler has an agreement in place and any minister‑set conditions are followed.
  • Would likely need to check which products are covered by agreements and comply with any extra conditions.

• Wholesalers and pharmacies

  • Wholesalers would need to sign risk management agreements, create and run compensation funds, indemnify the government for certain costs, and monitor and report on drug use as required.
  • If they choose not to enter an agreement, their drugs in affected classes could not be used in B.C. public programs and could not be prescribed, dispensed, or administered by practitioners.

• Public health programs and health authorities

  • Use of affected drugs (including COVID‑19 vaccines and safer‑supply medications) could proceed only if agreements are in place and conditions are met.
  • Additional tracking and reporting requirements may apply.

• Timing

  • The law would start on a date set by cabinet. Details of the agreements and conditions would be set later by regulation or ministerial decision.

• What is unclear

  • The exact terms of the required agreements, how the compensation fund would operate, which health‑system costs must be indemnified, what data must be reported, and how privacy will be protected are not detailed in the bill text.
  • One factor listed for designating drug classes (“potential for significant health care system costs”) appears incomplete in the text provided.

Expenses#

The bill may increase administrative and compliance costs, but no public fiscal estimate is provided.

• Government

  • Costs to design, negotiate, and enforce risk management agreements and to receive and analyze reports.
  • Possible cost recovery from wholesalers through indemnities if patients’ care leads to health‑system expenses.

• Wholesalers

  • Costs to establish and run compensation funds, provide indemnities, and meet monitoring/reporting duties.
  • Legal and administrative costs to negotiate and maintain agreements.

• Health care providers and programs

  • Time and administrative burden to verify agreement status and follow added conditions.
  • Potential program changes if agreements are not in place for certain drugs.

• Prices and supply

  • The bill could affect drug availability or pricing in B.C., but there is no clear information on the scale or likelihood.

Proponents' View#

• The bill appears intended to shift financial risk from patients and taxpayers to drug wholesalers when long‑term safety or effectiveness is uncertain.
• A required compensation fund could offer a clearer, faster path to payments for patients who are harmed.
• Indemnifying the government could protect the health budget from unexpected treatment and monitoring costs.
• Monitoring and reporting by wholesalers could improve safety oversight and accountability.
• Allowing the minister to add drug classes may help respond quickly to emerging public‑health risks.
• A conflict clause could ensure these protections apply even if another provincial law would otherwise prevent them.

Opponents' View#

• Labeling widely used medicines (such as COVID‑19 vaccines and SSRIs) as “experimental” in law may be seen as confusing or stigmatizing, and could be used to restrict access.
• Access could be disrupted if a wholesaler refuses or delays signing an agreement, affecting vaccinations, mental‑health treatment, harm‑reduction services, and gender‑affirming care.
• The minister has broad discretion to add drug classes and set conditions; the bill gives limited detail on criteria and safeguards, which may raise concerns about overreach or inconsistent application.
• Required reporting by wholesalers on prescribing and administration raises privacy questions; the bill does not specify what data will be collected, how it will be protected, or how long it will be kept.
• The conflict clause means this Act would override other provincial laws if they clash, which may create uncertainty about how it interacts with existing privacy or professional‑practice rules.
• Key operational details (exact agreement terms, scope of indemnity, how compensation funds will function) are left to regulations, making the real‑world impact hard to judge in advance.